Icotinib
| CAS No. | 610798-31-7 | Cat. No. | BCP21716 |
| Name | Icotinib | ||
| Synonyms | BPI2009; BPI 2009; BPI-2009;BPI-2009H;Conmana;Lcotinib; | ||
| Formula | C22H23N3O4 | M. Wt | 391.42 |
| Description | Icotinib, also known as BPI-2009, is an orally available quinazoline-based inhibitor of epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Icotinib selectively inhibits the wild-type and several mutated forms of EGFR tyrosine kinase. This may lead to an inhibition of EGFR-mediated signal transduction and may inhibit cancer cell proliferation. EGFR, a receptor tyrosine kinase, is upregulated in a variety of cancer cell types. | ||
| Related Products | 1204313-51-8（Icotinib Hydrochloride） | ||
| Pathways | Angiogenesis/Protein Tyrosine Kinase Jak/Stat Pathway | ||
| Targets | EGFR | ||
|
Comparison of the inhibition potentials of icotinib and erlotinib against human UDP-glucuronosyltransferase 1A1
Publications Citing of Biochempartner's Icotinib(CAS:610798-31-7) |
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.